257 related articles for article (PubMed ID: 25281917)
1. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers.
Dai X; Tan C
Adv Drug Deliv Rev; 2015 Jan; 81():184-97. PubMed ID: 25281917
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs and cancer stem cells: the sword and the shield.
Sun X; Jiao X; Pestell TG; Fan C; Qin S; Mirabelli E; Ren H; Pestell RG
Oncogene; 2014 Oct; 33(42):4967-77. PubMed ID: 24240682
[TBL] [Abstract][Full Text] [Related]
3. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).
Gambari R; Brognara E; Spandidos DA; Fabbri E
Int J Oncol; 2016 Jul; 49(1):5-32. PubMed ID: 27175518
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs.
Nana-Sinkam SP; Croce CM
IDrugs; 2010 Dec; 13(12):843-6. PubMed ID: 21154140
[TBL] [Abstract][Full Text] [Related]
5. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.
Adams BD; Parsons C; Slack FJ
Expert Opin Ther Targets; 2016 Jun; 20(6):737-53. PubMed ID: 26652031
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors.
Wang H; Jiang Y; Peng H; Chen Y; Zhu P; Huang Y
Adv Drug Deliv Rev; 2015 Jan; 81():142-60. PubMed ID: 25450259
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-induced drug resistance in gastric cancer.
Dehghanzadeh R; Jadidi-Niaragh F; Gharibi T; Yousefi M
Biomed Pharmacother; 2015 Aug; 74():191-9. PubMed ID: 26349984
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
Rupaimoole R; Slack FJ
Nat Rev Drug Discov; 2017 Mar; 16(3):203-222. PubMed ID: 28209991
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA: Promising Roles in Cancer Therapy.
Hashemi A; Gorji-Bahri G
Curr Pharm Biotechnol; 2020; 21(12):1186-1203. PubMed ID: 32310047
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of microRNAs in cancer.
Thorsen SB; Obad S; Jensen NF; Stenvang J; Kauppinen S
Cancer J; 2012; 18(3):275-84. PubMed ID: 22647365
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
Giovannetti E; Erozenci A; Smit J; Danesi R; Peters GJ
Crit Rev Oncol Hematol; 2012 Feb; 81(2):103-22. PubMed ID: 21546262
[TBL] [Abstract][Full Text] [Related]
12. Review of miR-200b and cancer chemosensitivity.
Feng B; Wang R; Chen LB
Biomed Pharmacother; 2012 Sep; 66(6):397-402. PubMed ID: 22795796
[TBL] [Abstract][Full Text] [Related]
13. microRNAs as pharmacological targets in cancer.
Soriano A; Jubierre L; Almazán-Moga A; Molist C; Roma J; de Toledo JS; Gallego S; Segura MF
Pharmacol Res; 2013 Sep; 75():3-14. PubMed ID: 23537752
[TBL] [Abstract][Full Text] [Related]
14. Exploiting the therapeutic potential of microRNAs in human cancer.
Cho WC
Expert Opin Ther Targets; 2012 Apr; 16(4):345-50. PubMed ID: 22339340
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
16. miRNAs: micro-managers of anticancer combination therapies.
van Beijnum JR; Giovannetti E; Poel D; Nowak-Sliwinska P; Griffioen AW
Angiogenesis; 2017 May; 20(2):269-285. PubMed ID: 28474282
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs and cancer resistance: A new molecular plot.
Fanini F; Fabbri M
Clin Pharmacol Ther; 2016 May; 99(5):485-93. PubMed ID: 26875151
[TBL] [Abstract][Full Text] [Related]
18. Nanotechnology applied to overcome tumor drug resistance.
Gao Z; Zhang L; Sun Y
J Control Release; 2012 Aug; 162(1):45-55. PubMed ID: 22698943
[TBL] [Abstract][Full Text] [Related]
19. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
20. Targeting the production of oncogenic microRNAs with multimodal synthetic small molecules.
Vo DD; Staedel C; Zehnacker L; Benhida R; Darfeuille F; Duca M
ACS Chem Biol; 2014 Mar; 9(3):711-21. PubMed ID: 24359019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
